MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ
45.76
-1.12
-2.39%
Opening 09:41 03/24 EDT
OPEN
46.18
PREV CLOSE
46.88
HIGH
46.38
LOW
45.12
VOLUME
125.27K
TURNOVER
--
52 WEEK HIGH
78.48
52 WEEK LOW
30.04
MARKET CAP
4.39B
P/E (TTM)
-7.0753
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRSP last week (0316-0320)?
Weekly Report · 1d ago
This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.
Barchart · 4d ago
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
NASDAQ · 4d ago
IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
TipRanks · 4d ago
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110
Benzinga · 03/17 13:32
Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler
TipRanks · 03/17 10:56
Crispr Therapeutics Completes $600 Million Convertible Notes Offering
TipRanks · 03/16 20:34
Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL
Seeking Alpha · 03/16 11:05
More
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Webull offers Crispr Therapeutics AG stock information, including NASDAQ: CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.